Contact Us Careers Register
Coherent Market Insights

U.K. Cell and Gene Therapy Research Challenges Market to Surpass US$ 2525 Million by 2028

U.K. Cell and Gene Therapy Research Challenges Market to Surpass US$ 2525 Million by 2028 - Coherent Market Insights

Publish In : Jan 28, 2022

Report ID : CMI4889

Category : Biotechnology

U.K. Cell and Gene Therapy Research Challenges Market to Surpass US$ 2525 Million by 2028

U.K. Cell and Gene Therapy Research Challenges Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), and by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others), is estimated to be valued at US$ 848 million in 2021 and is expected to exhibit a CAGR of 23.6% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Key players operating in the market are focusing on receiving product approvals from regulatory authorities and this is expected to drive the market growth over the forecast period.

For instance, in October 2021, Novartis AG, a global healthcare company, received priority review by the U.S. Food and Drug Administration (FDA) and Supplemental Biologics License Application (sBLA) and Type II Variation acceptance by European Medicines Agency (EMA) for ‘Kymriah’ for the treatment of patients with refractory or relapsed follicular lymphoma.

U.K. Cell and Gene Therapy Research Challenges Market – Impact of Coronavirus (COVID-19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 260,867,011 confirmed cases and 5,200,267 deaths due to Coronavirus (COVID-19) were reported up till November 29, 2021, across the globe.

The COVID-19 pandemic has negatively affected several markets across the globe including the UK cell and gene therapy market. The market is hampered due to disruptions in supply chain as well as manufacturing and logistics processes.

COVID-19 outbreak raised challenges in market authorization, price and reimbursement of cell and gene therapy. On the flip side, digitalization, innovative payment mechanisms, value-based pricing, telemedicine, and manufacturing resilience will be utilized to make sure that UK cell and gene therapy market access is not disrupted severely.

Browse 12 Market Data Tables and 18 Figures spread through 140 Pages and in-depth TOC on “Cell and Gene Therapy Research Challenges Market”- U.K. Forecast to 2028, U.K. Cell and Gene Therapy Research Challenges Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), and by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others)

To know the latest trends and insights prevalent in the U.K Cell and Gene Therapy Research Challenges Market for Hospitals & Ambulatory Settings, click the link below:

https://www.coherentmarketinsights.com/market-insight/uk-cell-and-gene-therapy-research-challenges-market-4889

Key players operating in the market are focusing on adoption of inorganic growth strategies such as mergers, collaborations, partnerships, and acquisitions, in order to strengthen their position in the U.K. market. For instance, in April 2020, Novartis AG, a Switzerland based global pharmaceutical company, entered into partnership agreement with TScan Therapeutics, a biopharmaceutical company, to develop T-cell receptor therapies for the treatment of solid tumors.

Key Takeaways of the U.K Cell and Gene Therapy Research Challenges Market:

  • The U.K. cell and gene therapy research challenges market is expected to exhibit a CAGR of 23.6% over the forecast period, owing to receiving grants by regulatory authorities. For instance,  In June 2020, Kite Pharma, Inc., a Gilead Company received U.S. Food and Drug Administration (FDA) approval for ‘Tecartus’ to treat adult patients with refractory or relapsed mantle cell lymphoma (MCL). Tecartus is the first and only approved chimeric antigen receptor (CAR) T cell therapy.
  • Among therapy type, cell therapy segment is expected to account for largest market share during the forecast period, owing to rise in adoption of inorganic strategies such as mergers, collaborations, partnerships, and acquisitions. For instance, in January 2018, Kite Pharma, Inc., a Gilead company, entered into a clinical trial collaboration with Pfizer, Inc., a biopharmaceutical company. An aim of this partnership is to evaluate investigational combination of Yescarta and Utomilumab of Pfizer in Large B-Cell Lymphoma.
  • Key players operating in the U.K. cell and gene therapy research challenges market include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., PTC Therapeutics, Inc., Orchard Therapeutics Plc., Biomarin Pharmaceutical Inc., Regeneron, Bluebird Bio, Inc. (Celgene Corporation), Freeline Therapeutics Ltd, MeiraGTx Limited, Kolon TissueGene, Inc., Kite Pharma, Inc. (Gilead Sciences, Inc.), Biogen Inc., and Bristol-Myers Squibb Company

ABOUT US:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

CONTACT US:

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

PHONE:

UK: +44-203-957-8553 / +44-203-949-5508

US: +1-252-477-1362

AUS: +61-8-7924-7805

INDIA: +91-848-285-0837

Email: [email protected]

Follow Us: LinkedIn | Twitter

Need more?

Speak to our analyst to understand how this research was put together
Add more segments or countries to the scope as part of free customization
Understand how this report can have a direct impact on your revenue

  • Supplier Analysis
  • Value Chain Analysis
  • Demand Analysis
  • Customer Intelligence
  • Trade Analysis
  • Pricing Analysis

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

EXISTING CLIENTELE

Created billion dollars of revenue impact on thousands of clients

trusted clients logo

LogoCredibility and Certifications

Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.

Reliability and Reputation

860519526

Reliability and Reputation
ISO 9001:2015

9001:2015

ISO 27001:2022

27001:2022

Reliability and Reputation
Reliability and Reputation
© 2025 Coherent Market Insights Pvt Ltd. All Rights Reserved.
Enquiry Icon Contact Us